Unsplash-colorful image_2018-11-30.jpg

Disclosure: Many publications were reviewed and found to be of strong merit. We chose to list only a few of these publications here based on independent review by the Beatty Laboratory and relevance to our work.

major scientific advances in pancreatic cancer

2019

MAR, 2019 Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer Nat Med 2019, March 4, 2019.

MAR, 2019 Protective autophagy elicited by Raf —> MEK —> ERK inhibition suggests a treatment strategy for RAS-driven cancers Nat Med 2019, March 4, 2019.

2018

DEC, 2018 FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer N Engl J Med 2018;379:2395-2406.

NOV, 2018 β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell. 2018 Nov 12;34(5):863-867.

NOV, 2018 Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Sci Transl Med. 2018 Oct 24;10(464).

NOV, 2018 RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2018 Nov 12;34(5):757-774.e7.

SEPT, 2018 Minimal functional driver gene heterogeneity among untreated metastases. Science. 2018 Sep 7;361(6406):1033-1037.

SEPT, 2018 Precancerous neoplastic cells can move through the pancreatic ductal system. Nature. 2018 Sep;561(7722):201-205.

JUL, 2018 Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology. 2018 Jul;155(1):29-32.

JUL, 2018 Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. 2018 Jul 17;49(1):178-193.e7.

JUN, 2018 Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018 Sep;8(9):1112-1129.

JUN, 2018 Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018 Jun;558(7711):600-604.

JUN, 2018 Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018 Jun 15;360(6394).

APR, 2018 The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018 Apr;8(4):403-416.

MAR, 2018 Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discov. 2018 Mar;8(3):276-287.

FEB, 2018 Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018 Feb 1;554(7690):62-68.

2017

DEC, 2017 Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell. 2017 Dec 11;32(6):824-839.e8.

DEC, 2017 Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Nov 23;551(7681):512-516.

DEC, 2017 Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017 Dec;7(12):1464-1479.

NOV, 2017 Glucose feeds the TCA cycle via circulating lactate. Nature. 2017 Nov 2;551(7678):115-118.

OCT, 2017 BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Cancer Discov. 2017 Oct;7(10):1184-1199.

SEPT, 2017 Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.

SEPT, 2017 MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 2017 Sep 11;32(3):392.

AUG, 2017 Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity. 2017 Aug 15;47(2):323-338.

AUG, 2017 Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 2017 Aug 24;170(5):875-888.e20.

2016

UNDER DEVELOPMENT

2015

UNDER DEVELOPMENT

2014

UNDER DEVELOPMENT

2013

UNDER DEVELOPMENT

2012

JAN, 2012 Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012 Jan 20;148(1-2):362-75.

JAN, 2012 EMT and dissemination precede pancreatic tumor formation. Cell. 2012 Jan 20;148(1-2):349-61.

MAR, 2012 Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Mar 20;21(3):418-29.

MAR, 2012 nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012 Mar;2(3):260-269.

APR, 2012 Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012 Apr 27;149(3):656-70.

JUN, 2012 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65.

JUN, 2012 Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012 Jun 12;21(6):822-35.

JUN, 2012 Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012 Jun 12;21(6):836-47.

JUL, 2012 RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012 Jul 26;487(7408):510-3.

SEPT, 2012 EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 2012 Sep 11;22(3):304-17.

SEPT, 2012 EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Sep 11;22(3):318-30.

NOV, 2012 Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15;491(7424):399-405.

2011

MAR, 2011 CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011 Mar 25;331(6024):1612-6.

APR, 2011 Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011 Apr 12;19(4):456-69.

APR, 2011 Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011 Apr 12;19(4):441-55.

APR, 2011 Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr;17(4):500-3.

MAY, 2011 FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25.

JUL, 2011 PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011 Jul;1(2):158-69.

2010

FEB, 2010 Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell. 2010 Feb 17;17(2):135-47.

OCT, 2010 Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010 Oct 28;467(7319):1114-7.

OCT, 2010 The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010 Oct 28;467(7319):1109-13.

NOV, 2010 Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell. 2010 Nov 16;18(5):448-58.

NOV, 2010 Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010 Nov 16;18(5):499-509.

NOV, 2010 Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010 Nov 5;330(6005):827-30.

2009

APR, 2009 Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009 Apr 10;324(5924):217.

APR, 2009 DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009 Apr 10;27(11):1806-13.

JUN, 2009 Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009 Jun 12;324(5933):1457-61.

JUN, 2009 Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009 Jun 10;27(17):2855-62.

2008

FEB, 2008 CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008 Feb;9(2):132-8.

SEPT, 2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801-6.

DEC, 2008 Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008 Dec 20;26(36):5918-22.

2007

JAN, 2007 Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17;297(3):267-77.

MAY, 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6.

2006

2005

MAY, 2005 Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005 May;7(5):469-83.

2004

MAR, 2004 A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18;350(12):1200-10.

2003

DEC, 2003 Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003 Dec;4(6):437-50.